Immix Biopharma 扩大了 AL 淀粉样变性治疗的美国试验地点，加快了研究进展。 Immix Biopharma expands U.S. trial sites for AL Amyloidosis treatment, accelerating study progress.

Immix Biopharma正在扩大其美国NEXICART-2临床试验场,这是治疗复发性/骨折性AL Amyloidis的试验。 Immix Biopharma is expanding its U.S. clinical trial sites for NEXICART-2, a trial for a treatment of relapsed/refractory AL Amyloidosis. 该公司增加了10个新站点,共有14个活跃站点,由于招生人数很多,预计提早完成试验。 The company has added 10 new sites, totaling 14 active sites, and expects to complete the trial early due to strong enrollment. 试验对NXC-201进行了评估,这一疗法没有表现出神经毒性,并且因其潜力得到了林业发展局和欧盟的特别指定。 The trial evaluates NXC-201, a therapy that has shown no neurotoxicity and has received special designations from the FDA and EU for its potential.